Apellis Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US03753U1060

Introduction

This page provides a comprehensive analysis of the known insider trading history of Watson David O.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Watson David O. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:APLS / Apellis Pharmaceuticals, Inc. General Counsel 123,730
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Watson David O.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases APLS / Apellis Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in APLS / Apellis Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APLS / Apellis Pharmaceuticals, Inc. Insider Trades
Insider Sales APLS / Apellis Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in APLS / Apellis Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2025-03-05 APLS Watson David O. 5,569 25.1013 5,569 25.1013 139,789 71 16.3600 -48,680 -34.82
2025-01-29 APLS Watson David O. 695 29.5236 695 29.5236 20,519
2025-01-22 APLS Watson David O. 3,323 30.4255 3,323 30.4255 101,104
2025-01-17 APLS Watson David O. 2,201 29.9582 2,201 29.9582 65,938
2025-01-13 APLS Watson David O. 4,965 28.7021 4,965 28.7021 142,506
2024-12-11 APLS Watson David O. 5,000 34.2350 5,000 34.2350 171,175
2024-02-12 APLS Watson David O. 781 67.7669 781 67.7669 52,926
2024-01-29 APLS Watson David O. 906 64.1382 906 64.1382 58,109
2024-01-22 APLS Watson David O. 4,184 64.9960 4,184 64.9960 271,943
2024-01-16 APLS Watson David O. 4,240 66.8086 4,240 66.8086 283,268
2023-12-19 APLS Watson David O. 1,605 57.0041 1,605 57.0041 91,492
2023-12-19 APLS Watson David O. 2,300 57.3827 2,300 57.3827 131,980
2022-06-22 APLS Watson David O. 10,000 44.5140 10,000 44.5140 445,140
2021-12-27 APLS Watson David O. 1,200 48.5000 1,200 48.5000 58,200
2021-12-22 APLS Watson David O. 5,174 47.7160 5,174 47.7160 246,883
2021-12-22 APLS Watson David O. 5,097 47.8550 5,097 47.8550 243,917
2021-12-22 APLS Watson David O. 300 48.5770 300 48.5770 14,573
2020-12-14 APLS Watson David O. 2,709 50.6070 2,709 50.6070 137,094
2020-12-14 APLS Watson David O. 2,526 51.3160 2,526 51.3160 129,624
2020-12-14 APLS Watson David O. 1,163 52.7270 1,163 52.7270 61,322
2020-12-14 APLS Watson David O. 900 53.8610 900 53.8610 48,475
2020-12-14 APLS Watson David O. 900 55.0010 900 55.0010 49,501
2020-12-14 APLS Watson David O. 200 55.9080 200 55.9080 11,182
2020-12-11 APLS Watson David O. 9,935 50.0000 9,935 50.0000 496,750
2018-09-14 APLS Watson David O. 15,776 18.7840 15,776 18.7840 296,336

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APLS / Apellis Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Watson David O. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2025-08-19 2025-08-18 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale X -5,000 123,730 -3.88 27.80 -139,000 3,439,694
2025-07-18 2025-07-16 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale X -5,000 128,730 -3.74 19.55 -97,750 2,516,672
2025-06-18 2025-06-16 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale X -5,000 133,730 -3.60 18.77 -93,850 2,510,112
2025-03-06 2025-03-05 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -5,569 138,730 -3.86 25.10 -139,789 3,482,303
2025-03-06 2025-03-04 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		G - Gift 6,667 10,000 200.03
2025-03-06 2025-03-04 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		G - Gift -6,667 0 -100.00
2025-01-30 2025-01-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -695 144,299 -0.48 29.52 -20,519 4,260,226
2025-01-23 2025-01-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -3,323 144,994 -2.24 30.43 -101,104 4,411,515
2025-01-21 2025-01-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		A - Award 42,762 148,317 40.51
2025-01-21 2025-01-17 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -2,201 105,555 -2.04 29.96 -65,938 3,162,238
2025-01-14 2025-01-13 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -4,965 107,756 -4.40 28.70 -142,506 3,092,823
2024-12-13 2024-12-11 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -5,000 112,721 -4.25 34.24 -171,175 3,859,003
2024-09-30 2024-09-27 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		G - Gift 10,569 117,721 9.86
2024-09-30 2024-09-27 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		G - Gift -10,569 70,136 -13.10
2024-03-08 2024-03-06 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 3,762 107,152 3.64 13.85 52,104 1,484,055
2024-02-13 2024-02-12 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -781 103,390 -0.75 67.77 -52,926 7,006,420
2024-01-31 2024-01-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -906 104,171 -0.86 64.14 -58,109 6,681,340
2024-01-23 2024-01-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -4,184 105,077 -3.83 65.00 -271,943 6,829,585
2024-01-17 2024-01-16 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -4,240 109,261 -3.74 66.81 -283,268 7,299,574
2024-01-17 2024-01-16 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		A - Award 23,748 113,501 26.46
2023-12-20 2023-12-19 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -2,300 89,753 -2.50 57.38 -131,980 5,150,269
2023-12-20 2023-12-19 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -1,605 92,053 -1.71 57.00 -91,492 5,247,398
2023-12-20 2023-12-19 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 7,905 93,658 9.22 13.85 109,484 1,297,163
2023-07-06 2023-07-03 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale X -8,510 85,753 -9.03 89.98 -765,730 7,716,055
2023-06-29 2023-06-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		G - Gift 12,750 80,705 18.76
2023-06-29 2023-06-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		G - Gift -12,750 94,263 -11.91
2023-04-24 2023-04-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		G - Gift 67,955 67,955
2023-04-24 2023-04-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		G - Gift -67,955 107,013 -38.84
2023-02-22 2023-02-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		F - Taxes -825 174,968 -0.47 58.50 -48,262 10,235,628
2023-02-22 2023-02-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		A - Award 9,886 175,793 5.96
2023-02-14 2023-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		F - Taxes -532 165,907 -0.32 51.21 -27,244 8,496,097
2023-01-30 2023-01-27 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		F - Taxes -551 166,439 -0.33 52.77 -29,076 8,782,986
2023-01-24 2023-01-20 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		F - Taxes -2,034 166,990 -1.20 52.05 -105,870 8,691,830
2023-01-17 2023-01-12 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		A - Award 29,452 169,024 21.10
2023-01-17 2023-01-12 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		A - Award 24,003 139,572 20.77
2022-06-23 2022-06-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -10,000 115,569 -7.96 44.51 -445,140 5,144,438
2022-04-27 2022-04-25 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale X -5,000 125,569 -3.83 50.00 -250,000 6,278,450
2022-04-27 2022-04-21 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		J - Other -11,250 0 -100.00
2022-04-27 2022-04-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		J - Other -1,875 130,569 -1.42
2022-02-14 2022-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		F - Taxes -491 132,444 -0.37 47.12 -23,136 6,240,761
2022-02-10 2021-12-08 5 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		G - Gift -3,333 3,333 -50.00
2022-02-01 2022-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		F - Taxes -650 132,935 -0.49 38.59 -25,084 5,129,962
2022-01-25 2022-01-21 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		A - Award 36,951 36,951
2022-01-25 2022-01-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		A - Award 26,051 133,585 24.23
2021-12-28 2021-12-27 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -1,200 107,534 -1.10 48.50 -58,200 5,215,399
2021-12-23 2021-12-22 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -5,397 14,888 -26.61
2021-12-23 2021-12-22 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -4,715 20,285 -18.86
2021-12-23 2021-12-22 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -4,826 11,667 -29.26
2021-12-23 2021-12-22 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -5,174 16,493 -23.88
2021-12-23 2021-12-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -300 108,734 -0.28 48.58 -14,573 5,281,972
2021-12-23 2021-12-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -5,097 109,034 -4.47 47.86 -243,917 5,217,822
2021-12-23 2021-12-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 5,397 114,131 4.96 14.95 80,685 1,706,258
2021-12-23 2021-12-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 4,715 108,734 4.53 14.95 70,489 1,625,573
2021-12-23 2021-12-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -5,174 104,019 -4.74 47.72 -246,883 4,963,371
2021-12-23 2021-12-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 4,826 109,193 4.62 13.85 66,840 1,512,323
2021-12-23 2021-12-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 5,174 104,367 5.22 13.85 71,660 1,445,483
2021-09-13 2021-09-10 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -954 0 -100.00
2021-09-13 2021-09-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 954 99,193 0.97 4.31 4,112 427,522
2021-06-22 2021-06-21 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -489 954 -33.89
2021-06-22 2021-06-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 489 98,239 0.50 4.31 2,108 423,410
2021-06-01 2021-05-28 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -489 1,443 -25.31
2021-06-01 2021-05-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 489 97,750 0.50 4.31 2,108 421,302
2021-04-23 2021-04-22 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -489 1,932 -20.20
2021-04-23 2021-04-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 489 97,261 0.51 4.31 2,108 419,195
2021-03-23 2021-03-22 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -978 2,421 -28.77
2021-03-23 2021-03-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 978 96,772 1.02 4.31 4,215 417,087
2021-02-11 2021-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		F - Taxes -468 95,794 -0.49 47.72 -22,333 4,571,290
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		A - Award 11,250 11,250
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		A - Award 45,000 45,000
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		A - Award 1,875 96,262 1.99
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		A - Award 7,500 94,387 8.63
2021-01-29 2021-01-27 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -20,042 3,399 -85.50
2021-01-29 2021-01-27 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -23,441 0 -100.00
2021-01-29 2021-01-27 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 20,042 86,887 29.98 4.31 86,381 374,483
2021-01-29 2021-01-27 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 23,441 66,845 54.01 3.76 88,138 251,337
2020-12-15 2020-12-14 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -8,398 21,667 -27.93
2020-12-15 2020-12-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -200 43,404 -0.46 55.91 -11,182 2,426,631
2020-12-15 2020-12-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -900 43,604 -2.02 55.00 -49,501 2,398,264
2020-12-15 2020-12-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -900 44,504 -1.98 53.86 -48,475 2,397,030
2020-12-15 2020-12-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -1,163 45,404 -2.50 52.73 -61,322 2,394,017
2020-12-15 2020-12-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -2,526 46,567 -5.15 51.32 -129,624 2,389,632
2020-12-15 2020-12-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -2,709 49,093 -5.23 50.61 -137,094 2,484,449
2020-12-15 2020-12-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 8,398 51,802 19.35 13.85 116,312 717,458
2020-12-15 2020-12-11 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -9,935 30,065 -24.84
2020-12-15 2020-12-11 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -9,935 43,404 -18.63 50.00 -496,750 2,170,200
2020-12-15 2020-12-11 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 9,935 53,339 22.89 13.85 137,600 738,745
2020-02-12 2020-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Stock option (right to buy) 		M - Exercise -7,505 0 -100.00
2020-02-12 2020-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Stock option (right to buy) 		A - Award 38,250 38,250
2020-02-12 2020-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 7,505 42,922 21.19 2.67 20,038 114,602
2020-02-12 2020-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale X -5,000 35,417 -12.37 44.50 -222,500 1,576,056
2020-02-12 2020-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		A - Award 6,375 40,417 18.73
2020-01-28 2020-01-27 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -15,000 7,505 -66.65
2020-01-28 2020-01-27 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 15,000 34,042 78.77 2.67 40,050 90,892
2020-01-28 2020-01-27 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale X -3,000 19,042 -13.61 40.47 -121,401 770,573
2019-08-09 2019-08-07 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		M - Exercise -5,000 22,505 -18.18
2019-08-09 2019-08-07 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 5,000 22,042 29.34 2.67 13,350 58,852
2019-02-12 2019-02-08 4 APLS Apellis Pharmaceuticals, Inc.
Stock option (right to buy) 		A - Award 40,000 40,000
2018-09-17 2018-09-14 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (right to buy) 		M - Exercise -32,818 27,505 -54.40
2018-09-17 2018-09-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		S - Sale -15,776 17,042 -48.07 18.78 -296,336 320,117
2018-09-17 2018-09-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 32,818 32,818 2.67 87,624 87,624
2018-05-30 2018-05-29 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (right to buy) 		M - Exercise -624 60,323 -1.02
2018-05-30 2018-05-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		G - Gift -624 0 -100.00
2018-05-30 2018-05-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		M - Exercise 624 624 2.67 1,666 1,666
2018-02-21 2018-02-16 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (right to buy) 		A - Award 25,000 25,000
2017-11-08 3 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		18,752
2017-11-08 3 APLS Apellis Pharmaceuticals, Inc.
Common Stock 		18,752
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)